Price transparency in high-cost therapies: striking a balance between innovation and access
Pharmaceutical price transparency has become one of the most contested issues in healthcare policy, and one…
Category Innovation
Pre-launch asset valuation: When BD&L need speed and Early Pipeline need depth
Two scenarios, both requiring pre-launch asset valuation: Scenario 1: Your BD&L team is evaluating a licensing…
Value-based pricing approaches for oncology products in Germany
Value-based pricing for oncology products in Germany requires a different approach to pre-launch price forecasting. GPI…
When traditional pricing methods fail: how Analogue Benchmarking solves the orphan drug pricing challenge
Phase 3 investment decisions for rare disease assets represent tens of millions in committed capital. Yet…
Navigating MFN: Turn risk into predictable outcomes
MFN pharmaceutical pricing exposure isn’t discovered — it’s built. The launch and pricing decisions teams make…
